Trial Profile
Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors TRPHARM
- 10 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as per decision of the sponsor
- 12 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
- 02 May 2017 New trial record